

Lupin Receives FDA Approval for Generic Rifadin® Capsules

Mumbai, Baltimore, August 23, 2013: Pharma Major Lupin Limited announced today that its U.S. subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has received final approval for its Rifampin Capsules USP, 150 mg and 300 mg strengths from the United States Food and Drugs Administration (FDA).

Lupin's Rifampin Capsules USP, 150 mg and 300 mg are the AB-rated generic equivalent of Sanofi Aventis' Rifadin® Capsules 150 mg and 300 mg strengths. Rifampin Capsules is indicated

- for the treatment of all forms of Tuberculosis
- for the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx

Rifadin® Capsules had annual U.S sales of approximately US\$ 18.5 million (IMS MAT Mar 2013). Lupin is one of the pioneers in the fight against Tuberculosis and holds global leadership positions in the Anti-TB segment.

About Lupin Limited

Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 5th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).

For the financial year ended March 2013, Lupin's Consolidated turnover and Profit after Tax were Rs. 94,616 million (USD 1.74 billion) and Rs. 13,142 million (USD 242 million) respectively. Please visit <http://www.lupinworld.com> for more information.

Lupin Pharmaceuticals, Inc. is the wholly owned U.S. subsidiary of Lupin Limited. Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visit <http://www.lupinpharmaceuticals.com>

For further information or queries please contact -

Shamsher Gorawara
Head – Corporate Communications
Lupin Limited
Ph: +91 98 20 338 555
Email: shamshergorawara@lupinpharma.com

or

Rajiv Pillai

Press Release



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

Head – Investor Relations

Lupin Limited

Ph: +91 98 20 552 083

Email: rajivpillai@lupinpharma.com

Safe Harbor Statement

Rifadin® Capsules, 150 mg and 300 mg, respectively are registered copyright of Sanofi Aventis U.S., Inc.